[评估布基纳法索两个卫生区淋巴丝虫病大规模治疗活动的治疗覆盖率]。

Medecine tropicale et sante internationale Pub Date : 2022-12-13 eCollection Date: 2022-12-31 DOI:10.48327/mtsi.v2i4.2022.174
Mamadou Serme, Adama Zida, Roland Bougma, Appolinaire Kima, Christophe Nassa, Micheline Ouedraogo, Cathérine Kabre, Harouna Zoromé, Issa Guire, Dieudonné Nare, Clarisse Bougouma
{"title":"[评估布基纳法索两个卫生区淋巴丝虫病大规模治疗活动的治疗覆盖率]。","authors":"Mamadou Serme, Adama Zida, Roland Bougma, Appolinaire Kima, Christophe Nassa, Micheline Ouedraogo, Cathérine Kabre, Harouna Zoromé, Issa Guire, Dieudonné Nare, Clarisse Bougouma","doi":"10.48327/mtsi.v2i4.2022.174","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & rationale: </strong>Burkina Faso has been implementing preventive chemotherapy against lymphatic filariasis since 2001. While 61 health districts (HDs) have stopped mass drug administration (MDA), transmission persists in 9 HDs despite good reported MDA coverage. To validate the reported coverage, an independent post-MDA survey was conducted in Tenkodogo and Fada N'Gourma HDs in September 2018.</p><p><strong>Materials & methods: </strong>The study population consisted of all persons in the visited communities. The Coverage survey sample builder (CSSB) tool was used to calculate the sample size and to conduct the random selection of households. A total of 30 villages per HD were selected. The investigators were Ministry of Education agents and health workers not involved in MDA. Data were collected on smartphones through the KoBoCollect application regarding age, sex, drug ingestion (ivermectin + albendazole), adverse events, and whether respondents understood MDA guidelines. Stata Version 14 software was used for data analysis.</p><p><strong>Results: </strong>A total of 3,741 individuals were surveyed, 53.3% were female and the median age was 14 years. Surveyed epidemiological coverage was 74% [95% CI: 72-76.1] in Fada N'Gourma and 79.1% [95% CI: 77.2-80.9] in Tenkodogo, compared to reported coverages of 82.6% and 83% respectively. Village-level coverage ranged from 32.9% to 100% in Fada N'Gourma and from 56.7% to 93.3% in Tenkodogo. In total, 99% of those treated said they had swallowed the drugs in front of the community drug distributor (CDD) and confirmed the use of dose poles. The main reasons for non-treatment were non-visitation of the compound by CDD (54%) and absences during MDA (43%). Results showed that surveyed coverage was lower than reported coverage in both HDs, yet both were above the 65% threshold recommended by WHO. However, major variations of coverage have been noted among villages. Directly observed treatment appeared to have been well respected.</p><p><strong>Discussion & conclusion: </strong>The main challenges to increase coverage will be the systematic revisiting of households with absentees and the targeting of all households in each village.</p>","PeriodicalId":18493,"journal":{"name":"Medecine tropicale et sante internationale","volume":"2 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940276/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].\",\"authors\":\"Mamadou Serme, Adama Zida, Roland Bougma, Appolinaire Kima, Christophe Nassa, Micheline Ouedraogo, Cathérine Kabre, Harouna Zoromé, Issa Guire, Dieudonné Nare, Clarisse Bougouma\",\"doi\":\"10.48327/mtsi.v2i4.2022.174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background & rationale: </strong>Burkina Faso has been implementing preventive chemotherapy against lymphatic filariasis since 2001. While 61 health districts (HDs) have stopped mass drug administration (MDA), transmission persists in 9 HDs despite good reported MDA coverage. To validate the reported coverage, an independent post-MDA survey was conducted in Tenkodogo and Fada N'Gourma HDs in September 2018.</p><p><strong>Materials & methods: </strong>The study population consisted of all persons in the visited communities. The Coverage survey sample builder (CSSB) tool was used to calculate the sample size and to conduct the random selection of households. A total of 30 villages per HD were selected. The investigators were Ministry of Education agents and health workers not involved in MDA. Data were collected on smartphones through the KoBoCollect application regarding age, sex, drug ingestion (ivermectin + albendazole), adverse events, and whether respondents understood MDA guidelines. Stata Version 14 software was used for data analysis.</p><p><strong>Results: </strong>A total of 3,741 individuals were surveyed, 53.3% were female and the median age was 14 years. Surveyed epidemiological coverage was 74% [95% CI: 72-76.1] in Fada N'Gourma and 79.1% [95% CI: 77.2-80.9] in Tenkodogo, compared to reported coverages of 82.6% and 83% respectively. Village-level coverage ranged from 32.9% to 100% in Fada N'Gourma and from 56.7% to 93.3% in Tenkodogo. In total, 99% of those treated said they had swallowed the drugs in front of the community drug distributor (CDD) and confirmed the use of dose poles. The main reasons for non-treatment were non-visitation of the compound by CDD (54%) and absences during MDA (43%). Results showed that surveyed coverage was lower than reported coverage in both HDs, yet both were above the 65% threshold recommended by WHO. However, major variations of coverage have been noted among villages. Directly observed treatment appeared to have been well respected.</p><p><strong>Discussion & conclusion: </strong>The main challenges to increase coverage will be the systematic revisiting of households with absentees and the targeting of all households in each village.</p>\",\"PeriodicalId\":18493,\"journal\":{\"name\":\"Medecine tropicale et sante internationale\",\"volume\":\"2 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940276/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medecine tropicale et sante internationale\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48327/mtsi.v2i4.2022.174\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/12/31 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine tropicale et sante internationale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48327/mtsi.v2i4.2022.174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/31 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景与理由:布基纳法索自 2001 年起开始实施淋巴丝虫病预防性化疗。虽然 61 个卫生区(HD)已停止大规模用药(MDA),但在 9 个卫生区,尽管报告的 MDA 覆盖率很高,传播仍然存在。为了验证所报告的覆盖率,2018年9月在滕科多戈(Tenkodogo)和法达-恩古尔马(Fada N'Gourma)卫生区进行了一次独立的MDA后调查:研究对象包括受访社区的所有人。覆盖率调查样本生成器(CSSB)工具用于计算样本量和随机选择住户。每个 HD 共抽取了 30 个村庄。调查人员为教育部人员和未参与 MDA 的卫生工作者。通过智能手机上的 KoBoCollect 应用程序收集有关年龄、性别、药物摄入量(伊维菌素 + 阿苯达唑)、不良反应以及受访者是否了解 MDA 指南的数据。数据分析采用 Stata 14 版软件:共调查了 3,741 人,其中 53.3% 为女性,年龄中位数为 14 岁。法达-恩古尔马的流行病学调查覆盖率为 74% [95% CI:72-76.1],滕科多戈为 79.1% [95% CI:77.2-80.9],而报告的覆盖率分别为 82.6% 和 83%。在法达-恩古尔马,村级覆盖率从 32.9% 到 100% 不等,在滕科多戈,村级覆盖率从 56.7% 到 93.3% 不等。总共有 99% 的接受治疗者表示,他们在社区药品分发员 (CDD) 面前吞下了药物,并确认使用了剂量杆。未接受治疗的主要原因是社区药品分发员(CDD)没有到访社区(54%)和在监测和评估期间缺席(43%)。结果表明,在两个人类发展区,调查覆盖率均低于报告覆盖率,但都高于世卫组织建议的 65% 临界值。然而,各村的覆盖率存在很大差异。讨论与结论:提高覆盖率所面临的主要挑战将是系统地重新访问缺席者家庭以及针对每个村庄的所有家庭。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].

[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].

[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].

[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].

Background & rationale: Burkina Faso has been implementing preventive chemotherapy against lymphatic filariasis since 2001. While 61 health districts (HDs) have stopped mass drug administration (MDA), transmission persists in 9 HDs despite good reported MDA coverage. To validate the reported coverage, an independent post-MDA survey was conducted in Tenkodogo and Fada N'Gourma HDs in September 2018.

Materials & methods: The study population consisted of all persons in the visited communities. The Coverage survey sample builder (CSSB) tool was used to calculate the sample size and to conduct the random selection of households. A total of 30 villages per HD were selected. The investigators were Ministry of Education agents and health workers not involved in MDA. Data were collected on smartphones through the KoBoCollect application regarding age, sex, drug ingestion (ivermectin + albendazole), adverse events, and whether respondents understood MDA guidelines. Stata Version 14 software was used for data analysis.

Results: A total of 3,741 individuals were surveyed, 53.3% were female and the median age was 14 years. Surveyed epidemiological coverage was 74% [95% CI: 72-76.1] in Fada N'Gourma and 79.1% [95% CI: 77.2-80.9] in Tenkodogo, compared to reported coverages of 82.6% and 83% respectively. Village-level coverage ranged from 32.9% to 100% in Fada N'Gourma and from 56.7% to 93.3% in Tenkodogo. In total, 99% of those treated said they had swallowed the drugs in front of the community drug distributor (CDD) and confirmed the use of dose poles. The main reasons for non-treatment were non-visitation of the compound by CDD (54%) and absences during MDA (43%). Results showed that surveyed coverage was lower than reported coverage in both HDs, yet both were above the 65% threshold recommended by WHO. However, major variations of coverage have been noted among villages. Directly observed treatment appeared to have been well respected.

Discussion & conclusion: The main challenges to increase coverage will be the systematic revisiting of households with absentees and the targeting of all households in each village.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信